Expert discussions are underway on the lifting of bans on cannabis-derived drugs in Japan. The government is set to create the environment needed to allow for the utilization of such medicines by embracing this policy in its annual “honebuto” paper,…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Notification Calls for Simultaneous Filing of Applications for Companion Diagnostics and Drugs
July 3, 2013
-
BUSINESS Japanese Society of Chemotherapy Joins Hands with Pharmas, Govt to Spur New Antibiotic Development
July 2, 2013
-
ORGANIZATION JMA Sets Up Pharmaceutical Affairs Section
July 1, 2013
-
BUSINESS Bayer Yakuhin to Shift Resources to Innovative New Drugs: President Brunn
June 28, 2013
-
ACADEMIA NHO Attains 30% Volume-Based Generic Target in FY2012
June 28, 2013
-
REGULATORY MHLW Maps Out New Vision for Pharma Industry; Research-Based Makers Will See “Survival of the Fittest,” It Says
June 27, 2013
-
BUSINESS Eisai to Suspend Sales of Future Mainstay Antiepileptic Drug in Germany
June 26, 2013
-
BUSINESS Filgrastim Biosimilars: Overseas Track Record vs. “Purely Made-in-Japan” Label
June 25, 2013
-
ACADEMIA Makers Should Venture into Drug Development Using iPS, CiRA Adviser Asonuma Says
June 25, 2013
-
REGULATORY FPMAJ May Find it Difficult to Compile Unified Statement of Views on TPP Talks Due to Disagreement among Original and Generic Drug Makers
June 24, 2013
-
ORGANIZATION JGA Concerned about TPP Talks, Hopes Japan Will Adopt US Rules Favorable to Generic Makers
June 24, 2013
-
ORGANIZATION JPMA Weighs Scheme to Allow Use of Clinical Research Evidence for Drug Applications
June 21, 2013
-
BUSINESS Anatomy of Mutual Reliance - Diovan Papers and Company Part 2: Explanations to the World Urged
June 21, 2013
-
REGULATORY MHLW to Resume Inviting Requests for Development of Unapproved Drugs, Indications; No Deadline Set This Time
June 20, 2013
-
BUSINESS Anatomy of Mutual Reliance - Diovan Papers and Company Part 1: A Blurred Line
June 20, 2013
-
BUSINESS Novartis Pharma to Voluntarily Refrain from Participation in JPMA’s Board of Directors Meeting
June 19, 2013
-
REGULATORY MHLW to Temporarily Withdraw Recommendation of Preventive Cervical Cancer Vaccinations
June 18, 2013
-
REGULATORY Cabinet Approves PM Abe’s Growth Strategy, Regulatory Reform Plan
June 17, 2013
-
BUSINESS ARBs Still Best Sellers in FY2012 Sales Ranking, Januvia Ranks in Top 10 after only 3 Years of Launch
June 14, 2013
-
REGULATORY CSIMC’s Expert Subcommittee on NHI Drug Pricing Affairs to Hold Hearings for Drug Pricing Organization at Next Meeting in July
June 14, 2013
ページ
“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…